These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 36189259)

  • 1. Defining and targeting patterns of T cell dysfunction in inborn errors of immunity.
    Campos JS; Henrickson SE
    Front Immunol; 2022; 13():932715. PubMed ID: 36189259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in CRISPR/Cas gene therapy for inborn errors of immunity.
    Liu X; Li G; Liu Y; Zhou F; Huang X; Li K
    Front Immunol; 2023; 14():1111777. PubMed ID: 37051232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Too much of a good thing: a review of primary immune regulatory disorders.
    Tsilifis C; Slatter MA; Gennery AR
    Front Immunol; 2023; 14():1279201. PubMed ID: 38022498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
    Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
    Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Edited T Cell Therapies for Inborn Errors of Immunity.
    Fox TA; Houghton BC; Booth C
    Front Genome Ed; 2022; 4():899294. PubMed ID: 35783679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leveraging Systems Immunology to Optimize Diagnosis and Treatment of Inborn Errors of Immunity.
    Mauracher AA; Henrickson SE
    Front Syst Biol; 2022; 2():. PubMed ID: 37670772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 guided genome and epigenome engineering and its therapeutic applications in immune mediated diseases.
    Singh DD; Hawkins RD; Lahesmaa R; Tripathi SK
    Semin Cell Dev Biol; 2019 Dec; 96():32-43. PubMed ID: 31112800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using CRISPR to enhance T cell effector function for therapeutic applications.
    Freen-van Heeren JJ
    Cytokine X; 2021 Mar; 3(1):100049. PubMed ID: 33604565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
    Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
    Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and efficient generation of antigen-specific isogenic T cells from cryopreserved blood samples.
    Eerkens AL; Vledder A; van Rooij N; Foijer F; Nijman HW; de Bruyn M
    Immunol Cell Biol; 2022 Apr; 100(4):285-295. PubMed ID: 35194830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
    Ren J; Zhao Y
    Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses to CRISPR-Cas protein.
    Roy S
    Prog Mol Biol Transl Sci; 2021; 178():213-229. PubMed ID: 33685598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of CRISPR systems in respiratory health: Entering a new 'red pen' era in genome editing.
    Moses C; Kaur P
    Respirology; 2019 Jul; 24(7):628-637. PubMed ID: 30883991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
    Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
    Jensen TI; Axelgaard E; Bak RO
    Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
    Ghaffari S; Khalili N; Rezaei N
    J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.